Background In patients with newly diagnosed multiple myeloma, the effect of adding
autologous stem-cell transplantation (ASCT) to triplet therapy (lenalidomide, bortezomib …

Multiple myeloma (MM) is a hematologic malignancy characterized by clonal proliferation of
plasma cells. MM is a heterogeneous disease, featured by various molecular subtypes with …

Simple Summary The assessment of responses is critical in patients diagnosed with multiple
myeloma. Nowadays, one of the most informative parameters to discriminate responses to …

Measurable residual disease (MRD) evaluation may help to guide treatment duration in
multiple myeloma (MM). Paradoxically, limited longitudinal data exist on MRD during …

Clonal hematopoiesis (CH) is an age-related condition driven by stem and progenitor cells
harboring recurrent mutations linked to myeloid neoplasms. Currently, potential effects on …

Measurable (or minimal) residual disease (MRD) in multiple myeloma (MM) refers to low
levels of myeloma cells detectable using advanced diagnostics. MRD testing is evolving …

Multiple myeloma (MM) is a prevalent bone marrow disorder. The challenges in managing
MM include selecting chemotherapy regimens that effectively modulate the myeloma …

Использование новых подходов в лечении рецидивов и рефрактерных форм
множественной миеломы (ММ) привело к существенному улучшению общей …

The impact of measurable residual disease (MRD) in relapse/refractory multiple myeloma
(RRMM) patients treated with T‐cell redirecting immunotherapy is uncertain. We analyzed …

Background The prognostic significance of minimal residual disease (MRD) status before
autologous hematopoietic stem cell transplantation (autoHCT) in patients with multiple …